• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

苯酞内酯与氟康唑及其新类似物的协同作用作为限制唑类药物用于治疗念珠菌病的一个因素

Synergic Effect of Phthalide Lactones and Fluconazole and Its New Analogues as a Factor Limiting the Use of Azole Drugs against Candidiasis.

作者信息

Krężel Piotr, Olejniczak Teresa, Tołoczko Aleksandra, Gach Joanna, Weselski Marek, Bronisz Robert

机构信息

Faculty of Biotechnology and Food Science, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland.

Faculty of Chemistry, University of Wrocław, F. Joliot-Curie 14, 50-383 Wrocław, Poland.

出版信息

Antibiotics (Basel). 2022 Oct 28;11(11):1500. doi: 10.3390/antibiotics11111500.

DOI:10.3390/antibiotics11111500
PMID:36358155
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9686652/
Abstract

The resistance of and other pathogenic yeasts to azole antifungal drugs has increased rapidly in recent years and is a significant problem in clinical therapy. The current state of pharmacological knowledge precludes the withdrawal of azole drugs, as no other active substances have yet been developed that could effectively replace them. Therefore, one of the anti-yeast strategies may be therapies that can rely on the synergistic action of natural compounds and azoles, limiting the use of azole drugs against candidiasis. Synergy assays performed in vitro were used to assess drug interactions Fractional Inhibitory Concentration Index. The synergistic effect of fluconazole () and three synthetic lactones identical to those naturally occurring in celery plants-3--butylphthalide (), 3--butylidenephthalide (), 3--butyl-4,5,6,7-tetrahydrophthalide ()-against ATCC 10231, ATCC 2091, and KKP 3390 was compared with the performance of the individual compounds separately. MIC (the amount of fungistatic substance (in µg/mL) inhibiting yeast growth by 90%) was determined as 5.96-6.25 µg/mL for fluconazole () and 92-150 µg/mL for lactones With the simultaneous administration of fluconazole () and one of the lactones , it was found that they act synergistically, and to achieve the same effect it is sufficient to use 0.58-6.73 µg/mL fluconazole () and 1.26-20.18 µg/mL of lactones . As fluconazole and phthalide lactones show synergy, 11 new fluconazole analogues with lower toxicity and lower inhibitory activity for CYP2C19, CYP1A2, and CYP2C9, were designed after in silico testing. The lipophilicity was also analyzed. A three-carbon alcohol with two rings was preserved. In all compounds 5-15, the 1,2,4-triazole rings were replaced with 1,2,3-triazole or tetrazole rings. The hydroxyl group was free or esterified with phenylacetic acid or thiophene-2-carboxylic acid chlorides or with adipic acid. In structures and the hydroxyl group was replaced with the fragment -CHCl or = CH. Additionally, the difluorophenyl ring was replaced with unsubstituted phenyl. The structures of the obtained compounds were determined by H NMR, and C NMR spectroscopy. Molecular masses were established by GC-MS or elemental analysis. The MIC and MIC of all compounds were determined against ATCC 10231, ATCC 2091, AM 38/20, KKP 3390, and KKP 3528. The MIC values for the newly prepared compounds ranged from 38.45 to 260.81 µg/mL. The 90% inhibitory dose was at least twice as high. Large differences in the effect of fluconazole analogues on individual strains were observed. A synergistic effect on three strains- ATCC 10231, ATCC 2091, KKP 339-was observed. Fractional inhibitory concentrations FIC and FIC were tested for the most active lactone, 3--butylphthalide, and seven fluconazole analogues. The strongest synergistic effect was observed for the strain ATCC 10231, FIC 0.04-0.48. The growth inhibitory amount of azole is from 25 to 55 µg/mL and from 3.13 to 25.3 µg/mL for 3--butylphthalide. Based on biological research, the influence of the structure on the fungistatic activity and the synergistic effect were determined.

摘要

近年来,白色念珠菌和其他致病性酵母菌对唑类抗真菌药物的耐药性迅速增加,这在临床治疗中是一个重大问题。目前的药理学知识状况使得唑类药物无法停用,因为尚未开发出其他能够有效替代它们的活性物质。因此,抗酵母菌策略之一可能是依赖天然化合物与唑类协同作用的疗法,从而限制唑类药物用于治疗念珠菌病。体外进行的协同试验用于评估药物相互作用的分数抑制浓度指数。将氟康唑()与三种与芹菜植物中天然存在的内酯相同的合成内酯——3 - 正丁基苯酞()、3 - 亚丁基苯酞()、3 - 正丁基 - 4,5,6,7 - 四氢苯酞()——对白色念珠菌ATCC 10231、热带念珠菌ATCC 2091和光滑念珠菌KKP 3390的协同作用与单独使用各化合物的效果进行了比较。氟康唑()的MIC(抑制酵母菌生长90%的抑菌物质的量(以μg/mL计))测定为5.96 - 6.25 μg/mL,内酯的MIC为92 - 150 μg/mL。同时给予氟康唑()和其中一种内酯时,发现它们具有协同作用,并且使用0.58 - 6.73 μg/mL氟康唑()和1.26 - 20.18 μg/mL内酯就足以达到相同效果。由于氟康唑和苯酞内酯显示出协同作用,在计算机模拟测试后设计了11种对CYP2C19、CYP1A2和CYP2C9毒性较低且抑制活性较低的新型氟康唑类似物。还分析了亲脂性。保留了带有两个环的三碳醇。在所有化合物5 - 15中,1,2,4 - 三唑环被1,2,3 - 三唑或四唑环取代。羟基是游离的,或者与苯乙酸、噻吩 - 2 - 羧酸氯或己二酸酯化。在结构和中,羟基被片段 -CHCl或 = CH取代。此外,二氟苯基环被未取代的苯基取代。通过1H NMR和13C NMR光谱测定所获得化合物的结构。通过GC - MS或元素分析确定分子量。测定了所有化合物对白色念珠菌ATCC 10231、热带念珠菌ATCC 2091、AM 38/20、光滑念珠菌KKP 3390和近平滑念珠菌KKP 3528的MIC和MFC。新制备化合物的MIC值范围为38.45至260.81 μg/mL。90%抑制剂量至少高两倍。观察到氟康唑类似物对各个菌株的作用存在很大差异。观察到对三种菌株——白色念珠菌ATCC 10231、热带念珠菌ATCC 2091、光滑念珠菌KKP 339——有协同作用。对活性最强的内酯3 - 正丁基苯酞和七种氟康唑类似物测试了分数抑制浓度FIC和FIC。在白色念珠菌ATCC 10231菌株中观察到最强的协同作用,FIC为0.04 - 0.48。唑类的生长抑制量为25至55 μg/mL,3 - 正丁基苯酞的生长抑制量为3.13至25.3 μg/mL。基于生物学研究,确定了结构对抑菌活性和协同作用的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/4ca79f362233/antibiotics-11-01500-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/945f372ded0b/antibiotics-11-01500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/6bda7192d6d7/antibiotics-11-01500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/631d8821eef2/antibiotics-11-01500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/df0a49a8741a/antibiotics-11-01500-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/b43068967eca/antibiotics-11-01500-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/a2205410bb18/antibiotics-11-01500-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/3a73e206c592/antibiotics-11-01500-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/f22ec5ca5df9/antibiotics-11-01500-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/2b8cac93eff6/antibiotics-11-01500-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/71643cce0380/antibiotics-11-01500-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/60d765c48682/antibiotics-11-01500-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/e6dc339077a4/antibiotics-11-01500-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/c442ab94b3c0/antibiotics-11-01500-g013a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/c218e8e4ba7c/antibiotics-11-01500-g014a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/375ed991d6a5/antibiotics-11-01500-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/4ca79f362233/antibiotics-11-01500-g016.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/945f372ded0b/antibiotics-11-01500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/6bda7192d6d7/antibiotics-11-01500-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/631d8821eef2/antibiotics-11-01500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/df0a49a8741a/antibiotics-11-01500-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/b43068967eca/antibiotics-11-01500-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/a2205410bb18/antibiotics-11-01500-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/3a73e206c592/antibiotics-11-01500-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/f22ec5ca5df9/antibiotics-11-01500-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/2b8cac93eff6/antibiotics-11-01500-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/71643cce0380/antibiotics-11-01500-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/60d765c48682/antibiotics-11-01500-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/e6dc339077a4/antibiotics-11-01500-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/c442ab94b3c0/antibiotics-11-01500-g013a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/c218e8e4ba7c/antibiotics-11-01500-g014a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/375ed991d6a5/antibiotics-11-01500-g015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fe1/9686652/4ca79f362233/antibiotics-11-01500-g016.jpg

相似文献

1
Synergic Effect of Phthalide Lactones and Fluconazole and Its New Analogues as a Factor Limiting the Use of Azole Drugs against Candidiasis.苯酞内酯与氟康唑及其新类似物的协同作用作为限制唑类药物用于治疗念珠菌病的一个因素
Antibiotics (Basel). 2022 Oct 28;11(11):1500. doi: 10.3390/antibiotics11111500.
2
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].念珠菌属对三唑类药物的抗真菌药敏谱:应用美国临床和实验室标准协会(CLSI)新的种特异性临床折点和流行病学截断值来表征抗真菌药物耐药性
Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682.
3
In vitro study on the potential fungicidal effects of atorvastatin in combination with some azole drugs against multidrug resistant Candida albicans.阿托伐他汀联合某些唑类药物对耐多药白色念珠菌体外潜在杀菌作用的研究。
World J Microbiol Biotechnol. 2021 Oct 11;37(11):191. doi: 10.1007/s11274-021-03158-4.
4
Fungistatic Effect of Phthalide Lactones on .香豆素类化合物对 的抑菌作用。
Molecules. 2023 Jul 15;28(14):5423. doi: 10.3390/molecules28145423.
5
In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.两性霉素 B 衍生物 K20 与唑类药物抗念珠菌属和新型隐球菌的体外协同抗真菌作用。
Med Mycol. 2015 Nov;53(8):837-44. doi: 10.1093/mmy/myv063. Epub 2015 Aug 10.
6
Antifungal activity of azole compounds CPA18 and CPA109 against azole-susceptible and -resistant strains of Candida albicans.唑类化合物 CPA18 和 CPA109 对唑类药物敏感和耐药的白念珠菌的抗真菌活性。
J Antimicrob Chemother. 2013 May;68(5):1111-9. doi: 10.1093/jac/dks506. Epub 2013 Jan 4.
7
Triazole Evolution of Candida parapsilosis Results in Cross-Resistance to Other Antifungal Drugs, Influences Stress Responses, and Alters Virulence in an Antifungal Drug-Dependent Manner.近平滑假丝酵母三唑类药物的演变导致对其他抗真菌药物的交叉耐药性,影响应激反应,并以抗真菌药物依赖的方式改变毒力。
mSphere. 2020 Oct 28;5(5):e00821-20. doi: 10.1128/mSphere.00821-20.
8
Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans.氧氟沙星和氟康唑对唑类耐药白色念珠菌的协同作用。 (注:原文中多了一个of,正确表述应该是Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. )
J Infect Chemother. 2000 Sep;6(3):151-4. doi: 10.1007/s101560070014.
9
Antifungal Activity and Potential Mechanism of N-Butylphthalide Alone and in Combination With Fluconazole Against .N-丁基苯酞单独及与氟康唑联合应用的抗真菌活性及潜在机制
Front Microbiol. 2019 Jul 2;10:1461. doi: 10.3389/fmicb.2019.01461. eCollection 2019.
10
Reversal of Azole Resistance in Candida albicans by Sulfa Antibacterial Drugs.磺胺类抗菌药物逆转白念珠菌的唑类耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.00701-17. Print 2018 Mar.

引用本文的文献

1
Fungistatic Effect of Phthalide Lactones on .香豆素类化合物对 的抑菌作用。
Molecules. 2023 Jul 15;28(14):5423. doi: 10.3390/molecules28145423.
2
Chemo-enzymatic synthesis and biological activity evaluation of propenylbenzene derivatives.丙烯基苯衍生物的化学酶法合成及生物活性评价
Front Microbiol. 2023 Jun 26;14:1223123. doi: 10.3389/fmicb.2023.1223123. eCollection 2023.

本文引用的文献

1
Antifungal Metabolites as Food Bio-Preservative: Innovation, Outlook, and Challenges.抗真菌代谢产物作为食品生物防腐剂:创新、前景与挑战
Metabolites. 2021 Dec 23;12(1):12. doi: 10.3390/metabo12010012.
2
Emerging issue of fluconazole-resistant candidemia in a tertiary care hospital of southern italy: time for antifungal stewardship program.意大利南部一家三级护理医院中出现的耐氟康唑念珠菌血症新问题:是时候开展抗真菌管理计划了。
J Mycol Med. 2022 Mar;32(1):101206. doi: 10.1016/j.mycmed.2021.101206. Epub 2021 Sep 16.
3
In Vitro Anti- Activity and Action Mode of Benzoxazole Derivatives.
苯并恶唑衍生物的体外抗活性和作用模式。
Molecules. 2021 Aug 18;26(16):5008. doi: 10.3390/molecules26165008.
4
Mechanisms of Azole Resistance and Trailing in Bloodstream Isolates.血流分离株中唑类耐药及拖尾现象的机制
J Fungi (Basel). 2021 Jul 28;7(8):612. doi: 10.3390/jof7080612.
5
Microbial Synthesis and Evaluation of Fungistatic Activity of 3-Butyl-3-hydroxyphthalide, the Mammalian Metabolite of 3--Butylidenephthalide.3-丁基-3-羟基邻苯二甲酸酐的微生物合成及抑菌活性评价,3--丁烯基邻苯二甲酸酐的哺乳动物代谢产物。
Int J Mol Sci. 2021 Jul 15;22(14):7600. doi: 10.3390/ijms22147600.
6
Molecular mechanism of fluconazole resistance and pathogenicity attributes of Lebanese Candida albicans hospital isolates.黎巴嫩白色念珠菌医院分离株的氟康唑耐药分子机制和致病性特征。
Fungal Genet Biol. 2021 Aug;153:103575. doi: 10.1016/j.fgb.2021.103575. Epub 2021 May 24.
7
Design, synthesis, and neuroprotective effects of novel hybrid compounds containing edaravone analogue and 3-n-butylphthalide ring-opened derivatives.新型含依达拉奉类似物和 3-正丁基苯酞开环衍生物的杂合化合物的设计、合成及神经保护作用。
Biochem Biophys Res Commun. 2021 Jun 4;556:99-105. doi: 10.1016/j.bbrc.2021.03.171. Epub 2021 Apr 8.
8
Antifungal therapy with azoles and the syndrome of acquired mineralocorticoid excess.唑类抗真菌治疗与获得性盐皮质激素过多综合征。
Mol Cell Endocrinol. 2021 Mar 15;524:111168. doi: 10.1016/j.mce.2021.111168. Epub 2021 Jan 21.
9
DL-3-n-butylphthalide ameliorates diabetes-associated cognitive decline by enhancing PI3K/Akt signaling and suppressing oxidative stress.DL-3-n-丁基邻苯二甲酸二乙酯通过增强 PI3K/Akt 信号通路和抑制氧化应激改善糖尿病相关认知功能下降。
Acta Pharmacol Sin. 2021 Mar;42(3):347-360. doi: 10.1038/s41401-020-00583-3. Epub 2021 Jan 18.
10
Dl-3-n-butylphthalide inhibits neuroinflammation by stimulating foxp3 and Ki-67 in an ischemic stroke model.二正丁基苯酞通过刺激缺血性脑卒中模型中的 Foxp3 和 Ki-67 抑制神经炎症。
Aging (Albany NY). 2021 Jan 10;13(3):3763-3778. doi: 10.18632/aging.202338.